Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels

Ann Oncol. 2019 Jan 1;30(1):155-156. doi: 10.1093/annonc/mdy468.

¹ Departments of Clinical Neurosciences, Lausanne, Switzerland; Oncology, CHUV University Hospital & University of Lausanne, Lausanne, Switzerland. Electronic address: andreas.hottinger@gmail.com.
² Oncology, CHUV University Hospital & University of Lausanne, Lausanne, Switzerland.
³ Department of Neuropathology, Institut du Cerveau et de la Moelle Épinière, ICM, AP-HP, Sorbonne Université, INSERM, CNRS, UMR S 1127, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France.
⁴ Department of Pharmacology, CHUV University Hospital & University of Lausanne, Lausanne, Switzerland.
⁵ Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle èpiniére, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtriêre - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
⁶ Malnati Brain Tumor Institute of the Lurie Compr. Cancer Cent, Departments of Neurological Surgery, Neurology and Oncology, Northwestern University, Chicago, USA.

No abstract available

Publication types